Utility of LymphoTrack for clonality testing in formalinfixed, paraffin-embedded tissue: integrated panel- and specimen-level comparison with fragment analysis

Background: Next-generation sequencing-based clonality assays provide sequence-level resolution but remain vulnerable to panel-specific failure in formalin-fixed, paraffin-embedded (FFPE) tissue. We evaluated LymphoTrack performance and integrated multi-panel interpretation. Methods: Seventeen FFPE specimens from 16 patients underwent 51 immunoglobulin heavy-chain (IGH) and 12 T-cell receptor (TCR) panel runs. Results were classified as Positive, Negative, or Fail and compared with lineage-level fragment-analysis interpretations. Panels targeting each lineage were integrated into specimen-level interpretations. Quality-control metrics associated with panel failure were explored. Results: Among 51 IGH panel runs, 37 (72.5%) were concordant, four (7.8%) discordant, and 10 (19.6%) Fail; all Fail results occurred in FR1 or FR2. IGH specimen-level agreement was 16/17 (94.1%; 95% confidence interval [CI], 73.0% to 99.0%). LymphoTrack classified four IGH specimens as monoclonal and 13 as polyclonal, including six based on incomplete panel coverage. One such specimen (FR1/FR2 Fail and FR3 Negative) was discordant with monoclonal fragment analysis. TCR specimen-level agreement was 5/6 (83.3%; 95% CI, 43.6% to 97.0%). In the discordant TCR specimen, T-cell receptor gamma (TRG) fragment analysis was oligoclonal, whereas both LymphoTrack TRG and T-cell receptor beta were Positive. A post-polymerase chain reaction library concentration threshold of ≤4.5 ng/μL identified all Fail panels but had limited specificity (58.5%) and precision (31.3%). Conclusions: LymphoTrack showed high specimen-level agreement with fragment analysis despite panel-specific technical vulnerability in FFPE tissue. Partial panel failure had asymmetric implications: a Positive panel preserved a monoclonal interpretation, whereas polyclonal results with incomplete panel coverage remained vulnerable to discordance. Reporting incomplete panel coverage may help communicate this limitation.

Authors

Institutions

Publication Details

Journal
Journal of Pathology and Translational Medicine
Published
2026-11-13
DOI
https://doi.org/10.4132/jptm.2026.10.02
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Utility of LymphoTrack for clonality testing in formalinfixed, paraffin-embedded tissue: integrated panel- and specimen-level comparison with fragment analysis

Jiwon Koh, Jeong Mo Bae, Yoon Kyung Jeon, Seung Geun Song et al.
Journal of Pathology and Translational Medicine
Lymphoma Diagnosis and Treatment
article

Utility of LymphoTrack for clonality testing in formalinfixed, paraffin-embedded tissue: integrated panel- and specimen-level comparison with fragment analysis

Jiwon Koh, Jeong Mo Bae, Yoon Kyung Jeon, Seung Geun Song, Chul Lee, Hyun-A Kim, Ki-Chang Lee
article en

Abstract

Background: Next-generation sequencing-based clonality assays provide sequence-level resolution but remain vulnerable to panel-specific failure in formalin-fixed, paraffin-embedded (FFPE) tissue. We evaluated LymphoTrack performance and integrated multi-panel interpretation. Methods: Seventeen FFPE specimens from 16 patients underwent 51 immunoglobulin heavy-chain (IGH) and 12 T-cell receptor (TCR) panel runs. Results were classified as Positive, Negative, or Fail and compared with lineage-level fragment-analysis interpretations. Panels targeting each lineage were integrated into specimen-level interpretations. Quality-control metrics associated with panel failure were explored. Results: Among 51 IGH panel runs, 37 (72.5%) were concordant, four (7.8%) discordant, and 10 (19.6%) Fail; all Fail results occurred in FR1 or FR2. IGH specimen-level agreement was 16/17 (94.1%; 95% confidence interval [CI], 73.0% to 99.0%). LymphoTrack classified four IGH specimens as monoclonal and 13 as polyclonal, including six based on incomplete panel coverage. One such specimen (FR1/FR2 Fail and FR3 Negative) was discordant with monoclonal fragment analysis. TCR specimen-level agreement was 5/6 (83.3%; 95% CI, 43.6% to 97.0%). In the discordant TCR specimen, T-cell receptor gamma (TRG) fragment analysis was oligoclonal, whereas both LymphoTrack TRG and T-cell receptor beta were Positive. A post-polymerase chain reaction library concentration threshold of ≤4.5 ng/μL identified all Fail panels but had limited specificity (58.5%) and precision (31.3%). Conclusions: LymphoTrack showed high specimen-level agreement with fragment analysis despite panel-specific technical vulnerability in FFPE tissue. Partial panel failure had asymmetric implications: a Positive panel preserved a monoclonal interpretation, whereas polyclonal results with incomplete panel coverage remained vulnerable to discordance. Reporting incomplete panel coverage may help communicate this limitation.

Journal of Pathology and Translational Medicine
Seoul National University (KR), Seoul National University Hospital (KR)
Good health and well-being
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon